About Us

Mediomics, LLC provides innovative assay kits and biosensors needed by academic research laboratories, point of care testing, pharmaceutical companies, as well as medical and environmental research markets. These quick and simple assay kits will be used to quantify many biologically and therapeutically important macromolecules, including DNA, biomarkers, hormones, antibodies, intracellular signaling molecules, protein-protein complexes, bacteria, fungi, and viruses.

Mediomics currently holds four core proprietary technologies:

1. Bridge-It®, a sensitive and rapid mix-and–measure DNA-binding protein assay platform

2. PINCER®, a rapid mix-and–measure biosensor, bioassay and biochip platform

3. Innovative, proprietary methods to screen and develop new high-affinity capture reagents for research, diagnostic, and therapeutic use

4. Anti-angiogenesis related therapies

Our platform technologies have already been adapted for the detection of a range of important macromolecules, including cAMP, tryptophan, S-adenosyl methionine, PDE, biotin, insulin, C-peptide, albumin, C-reactive protein (hCRP), IgG, IgM, E. coli, and others.

In addition, Mediomics’ platform technologies will be able to generate entirely new biomaterials, which can be used for assay development as well as for the development of therapeutic products. Mediomics has successfully competed for a number of highly selective state and federal grants and subcontracts (nearly $6.5 million in total), with awards to date including SBIR Phase I and II grants from the National Science Foundation, STTR Phase I and II grants from the National Institutes of Health, subcontracts from the Department of Homeland Security, and a subcontract from the Leonard Wood Institute.

Dr. Yie-Hwa Chang founded the company in August 2001 as a Missouri Limited Liability Corporation (LLC).